Active Biotech Interim Report Q2 2024
SECOND QUARTER IN BRIEF
- Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)
- Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22)
- Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer were presented at ASCO 2024 (May 28)
EVENTS AFTER THE END OF THE PERIOD
- Active Biotech entered agreement for a clinical study of tasquinimod in myelofibrosis (July 1)
- Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15)
FINANCIAL SUMMARY
SEK M | Apr-Jun | Jan-Jun | Full-year | ||
2024 2023 | 2024 2023 | 2023 | |||
Net sales | – | – | – | – | – |
Operating profit/loss | -10.7 | -11.3 | -21.4 | -23.1 | -46.5 |
Profit/loss after tax | -10.6 | -11.2 | -21.1 | -22.7 | -45.8 |
Earnings per share (SEK) | -0.03 | -0.04 | -0.06 | -0.09 | -0.17 |
Cash and cash equivalents (at close of period) | 13.9 | 15.7 | 36.2 |
The report is also available at www.activebiotech.com